{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:32:04Z","timestamp":1792150324814,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.clinthera.2013.12.004","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T05:03:35Z","timestamp":1389416615000},"page":"115-125","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Ketoconazole on the Pharmacokinetic Properties of CG100649, A Novel NSAID: A Randomized, Open-Label Crossover Study in Healthy Korean Male Volunteers"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01154764","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hee Youn","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Joon","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ah","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Un-Jib","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ju","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yook-Hwan","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun-Seop","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.12.004_bib1","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.joca.2011.08.009","article-title":"The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review","volume":"19","author":"Pereira","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.clinthera.2013.12.004_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10067-006-0240-3","article-title":"The burden of musculoskeletal disease\u2014a global perspective","volume":"25","author":"Brooks","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2013.12.004_bib3","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/01.blo.0000143938.30681.9d","article-title":"The impact of osteoarthritis: implications for research","author":"Buckwalter","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.clinthera.2013.12.004_bib4","first-page":"49","article-title":"Osteoarthritis: diagnosis and treatment","volume":"85","author":"Sinusas","year":"2012","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2013.12.004_bib5","first-page":"841","article-title":"Osteoarthritis: diagnosis and therapeutic considerations","volume":"65","author":"Hinton","year":"2002","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2013.12.004_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2013.12.004_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/rheumatology\/37.5.546","article-title":"The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness","volume":"37","author":"Scott","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clinthera.2013.12.004_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(91)90744-A","article-title":"Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding","volume":"337","author":"Laporte","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.12.004_bib9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.158.10.1108","article-title":"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics","volume":"158","author":"Heerdink","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2013.12.004_bib10","first-page":"1177","article-title":"Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?","volume":"53","author":"Hunt","year":"2007","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.clinthera.2013.12.004_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1160\/TH06-08-0444","article-title":"The pharmacology of selective inhibition of COX-2","volume":"96","author":"Grosser","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2013.12.004_bib12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.12.004_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archinte.165.2.171","article-title":"National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation","volume":"165","author":"Dai","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2013.12.004_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000086459","article-title":"Selective COX-2 inhibitors and risk of myocardial infarction","volume":"42","author":"Krotz","year":"2005","journal-title":"J Vasc Res"},{"key":"10.1016\/j.clinthera.2013.12.004_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1185\/03007995.2013.785391","article-title":"The complexities in the pharmacologic management of osteoarthritis pain","volume":"29","author":"McCarberg","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.12.004_bib16","first-page":"395","article-title":"The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk","volume":"27","author":"Greenberg","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2013.12.004_bib17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/clpt.2012.3","article-title":"Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649","volume":"91","author":"Skarke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.12.004_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2013.12.004_bib19","unstructured":"US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf. Accessed March 11, 2013."},{"key":"10.1016\/j.clinthera.2013.12.004_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2013.12.004_bib21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \"ideal\" body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2013.12.004_bib22","first-page":"45","article-title":"Harmonized tripartite guideline: Guideline for Good Clinical Practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.clinthera.2013.12.004_bib23","first-page":"41","article-title":"[The Helsinki Declaration]","volume":"29","year":"2010","journal-title":"Assist Inferm Ric"},{"key":"10.1016\/j.clinthera.2013.12.004_bib24","unstructured":"Korea Food and Drug Administration. Analytical procedure validation guideline [in Korean]. http:\/\/kfda.go.kr\/index.kfda?mid=563&pageNo=83&seq=4521&cmd=v. Accessed March 22, 2013."},{"key":"10.1016\/j.clinthera.2013.12.004_bib25","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland","year":"2011"},{"key":"10.1016\/j.clinthera.2013.12.004_bib26","unstructured":"Korea Food and Drug Administration. Drug-drug interaction study guideline in Korea [in Korean]. http:\/\/kfda.go.kr\/index.kfda?mid=563&pageNo=75&seq=4576&cmd=v. Accessed March 21, 2013."},{"key":"10.1016\/j.clinthera.2013.12.004_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbagen.2006.09.024","article-title":"The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks","volume":"1770","author":"Plant","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2013.12.004_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389200043335450","article-title":"Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4","volume":"5","author":"Zhou","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2013.12.004_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2013.12.004_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.clpt.6100054","article-title":"Drug interaction studies: study design, data analysis, and implications for dosing and labeling","volume":"81","author":"Huang","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.12.004_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2013.12.004_bib32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition","volume":"34","author":"Galetin","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2013.12.004_bib33","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.112.050732","article-title":"Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole","volume":"41","author":"Bing","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2013.12.004_bib34","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/dmd.105.008730","article-title":"Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole","volume":"34","author":"Jenny","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2013.12.004_bib35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","article-title":"Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm","volume":"49","author":"Stoch","year":"2009","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:13:30Z","timestamp":1746108810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813011193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0149291813011193"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.12.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}